Inizio’s Post

Dear network, are you heading to #AACR in #SanDiego next week? Please join my colleagues Ankush Madaan PhD, B.Pharm Marijana Rucevic and Antoine Italiano from #GustaveRoussy for an exciting seminar on how Olink Proteomics #PEA #technology can aid early cancer detection with minimal #biosample input. #cancerproteomics #earlydetection #aacr24 #oncology

I am glad to share my second article that was published in the International Journal of Biological Macromolecules. Title:''Preparation and characterization of pH-sensitive chitosan/starch/MoS2 nanocomposite for control release of curcumin macromolecules drug delivery; application in the breast cancer treatment'' #Drug_Delivery #Breast_cancer_treatment #Nanoparticles #Curcumin https://lnkd.in/emgwJa-E

Delighted to share our latest paper on “Tumor-agnostic drug development in dMMR/MSI-H solid tumors” just published in Trends in Cancer – Vivek Subbiah, MD #cancer #immunotherapy #drugs #research #precisionmedicine #trendsincancer #tumoragonostic #tumor #oncology #oncodaily

The Blood Profiling Atlas in Cancer (BLOODPAC) supports the management, analysis and sharing of liquid biopsy data for the oncology research community and aims to accelerate discovery and development of therapies, diagnostic tests, and other technologies for cancer treatment and prevention. #liquidbiopsy #ctDNA #cfDNA #oncology #cancerresearch

Join us tomorrow for a webinar to discuss the developments of Q3 thus far. We will be looking further into Sona's biocompatible nanoparticle technology which is being used to develop cancer therapies & rapid diagnostics. Register for the opportunity to gain insights and ask questions of management: https://bit.ly/3Dx64JI #colorectalcancercanada #oncology #oncologyresearch #cancertreatment #cancerresearch #healthcare #GastroHealth #clinicaltrials #cancerresearchuk

Just wanted to share an educational post, please feel free to reshare. This case is visualizing Novartis theranostics agent PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) HCP taken at two time points using #PSMA #petct as an imaging tool. NCPIC’s clinical team found a favorable partial response for prostate cancer (in terms of bone and nodal metastasis) using a new treatment method called “theranostics” as a treating agent. It's amazing to see how technology is helping us better understand cancer therapy effectiveness. #prostatecancer #menshealth #novartis #psma #petct #theranostics

Discover best practices to investigate novel blood cancer therapies with hematology experts Christopher Morley and Sari Heitner Enschede, MD. This insightful white paper explores how biotech companies can address the challenges around investigational agents for hematologic cancers, while considering patient diversity. https://bit.ly/4cRuptj #oncology #hematology #biotech #ClinicalTrials #diversity

The primary goal of ex vivo testing is to predict how an individual patient's tumor will respond to different treatment options. By exposing the tumor cells to a panel of drugs with 3D Predict™, we can identify which are most effective against that patient's specific cancer. Let's put functional precision medicine to work for your patients: [email protected] #3DPredict #Kiyatec #PrecisionMedicine #Oncology #CancerTreatment